GLP-1 & Cancer Study

A recent study indicates that GLP-1 weight loss medications, such as Semaglutide and Tirzepatide, are associated with a lower risk of certain cancers, particularly among individuals with obesity.

Key Findings of the Study

• Research Overview: Conducted by researchers at the University of Florida, the study analyzed data from over 86,000 adults with obesity or who were overweight, comparing those using GLP-1 medications to those who were not. The findings were published in JAMA Oncology.

• Cancer Risk Reduction: The study found that users of GLP-1 medications had a 17% lower overall cancer risk compared to non-users. This reduction was particularly significant for specific types of cancers:

• Endometrial Cancer: Approximately 25% risk reduction.

• Ovarian Cancer: About 47% risk reduction.

• Meningioma: Around 31% risk reduction.

• However, there was an observed increased risk of kidney cancer among users.

• Broader Implications: This study is notable as it is one of the first to examine the association between GLP-1 receptor agonist (GLP-1RA) use and cancer risk in a broad population, rather than focusing solely on patients with type 2 diabetes.

Additional Context

• Mechanism of Action: Experts suggest that GLP-1 medications may reduce inflammation, a known risk factor for various cancers, thereby potentially lowering the risk of obesity-related cancers.

• Comparison with Other Treatments: Another study indicated that GLP-1 drugs could lower the risk of obesity-related cancer by 41% compared to bariatric surgery, although this figure adjusted to 13% when considering blood sugar management.

Conclusion

The findings from this study suggest that GLP-1 weight loss medications not only aid in weight management but may also provide significant benefits in reducing the risk of certain cancers associated with obesity. However, further research is needed to fully understand the implications and mechanisms behind these findings. For more detailed information, you can read the full study published in JAMA Oncology.

University of Florida Health University of Florida.